TACE combined with regorafenib and PD-1 second-line sequential therapy for advanced hepatocellular carcinoma:a clinical study
10.3969/j.issn.1008-794X.2024.09.013
- VernacularTitle:TACE联合瑞戈非尼及PD-1二线序贯治疗中晚期肝细胞癌的临床研究
- Author:
Jiapeng SHI
1
;
Xiaoxing TANG
;
Zhuxin GU
;
Rongfeng SHI
;
Xiaohua LU
;
Hui ZHAO
Author Information
1. 226001 江苏南通 南通市中医院介入科
- Keywords:
hepatocellular carcinoma;
transarterial chemoembolization;
regorafenib;
programmed death receptor-1;
clinical efficacy;
safety
- From:
Journal of Interventional Radiology
2024;33(9):995-1000
- CountryChina
- Language:Chinese
-
Abstract:
Objective To discuss the effectiveness and safety of transarterial chemoembolization(TACE)combined with regorafenib and programmed death receptor-1(PD-1)in the second-line sequential treatment of advanced hepatocellular carcinoma(HCC).Methods The clinical data of a total of 83 patients with advanced HCC,who received TACE combined with regorafenib and PD-1(triple-therapy group)or TACE combined with regorafenib(dual-therapy group)at the Affiliated Hospital of Nantong University and Nantong Municipal Third People's Hospital of China between October 2020 and May 2022,were retrospectively analyzed.The clinical data were collected and evaluated.Modified response evaluation criteria in solid tumors(mRECIST)was used to evaluate the curative effect.The progression-free survival(PFS),overall survival(OS)and treatment-related adverse events(TRAEs)were compared between the two groups.The Kaplan-Meier method was used to draw PFS and OS curves,the Log-rank test was used to compare the relevant data between the two groups,and the COX regression model was drawn to determine the factors influencing PFS and OS.Results There were no statistically significant differences in the baseline data between the two groups(P≥0.05).In the triple-therapy group and the dual-therapy group,the objective response rate(ORR)was 31.1％and 18.4％respectively(P=0.024),and the disease control rate(DCR)was 77.8％and 57.8％respectively(P=0.038).The OS and PFS in the triple-therapy group were higher than those in the dual-therapy group(16.80 months vs 13.20 months,and 9.10 months vs.7.40 months,respectively).No statistically significant difference in the incidence of adverse drug reactions existed between the two groups(P 0.05).Conclusion In the second-line sequential treatment of advanced HCC,TACE combined with regorafenib and PD-1 is more effective than TACE combined with regorafenib,therefore,it can be used as a preferred second-line treatment for advanced HCC.
